about
Chelation in metal intoxicationDeferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing iron overload in people with thalassaemiaDeferasirox for managing transfusional iron overload in people with sickle cell diseaseTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesIron chelation and multiple sclerosisPharmacology of iron transportCurrent and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Future alternative therapies for β-thalassemia.Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model.Iron chelation therapy in myelodysplastic syndromes.The oral iron chelator deferiprone protects against iron overload-induced retinal degenerationDesferrithiocin: a search for clinically effective iron chelators.Synthesis and iron sequestration equilibria of novel exocyclic 3-hydroxy-2-pyridinone donor group siderophore mimics.Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retinaMetabolically programmed iron chelatorsModel-Based Optimisation of Deferoxamine Chelation Therapy.Korean guideline for iron chelation therapy in transfusion-induced iron overload.Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation.Production of metabolites as bacterial responses to the marine environment.Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice.Deferasirox: pharmacokinetics and clinical experience.Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.Deferasirox for managing iron overload in people with thalassaemia.Can multi-slice or navigator-gated R2* MRI replace single-slice breath-hold acquisition for hepatic iron quantification?Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups.The Stomatological Complications of Diamond-Blackfan Anemia: A Case Report.Iron overload in patients undergoing hematopoietic stem cell transplantation.Deferasirox use after hematopoietic stem cell transplantation in pediatric patients with beta-thalassemia major: preliminary results.Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.
P2860
Q22305611-51C99A61-CAAC-4D2E-8FEE-B74F072F5966Q24194549-E42BCBF5-210D-46B2-AE9C-51AB343EBF9CQ24203718-D6D59B6B-89CA-4019-82D3-7EA7F261DED3Q24236463-4C35D74C-11D2-48A1-8337-F55E74E70096Q24289511-71331079-F90D-4703-8355-9690DFA6DF9DQ27001743-C44313A6-877E-4CE3-8831-7ADCF12D9081Q27009387-2B91D2C1-7641-4399-927E-33EF50BC8D92Q30277969-E2D53F3D-9E1F-48DF-8681-A01F47C582E1Q33659678-EB692D64-CBAF-4074-ABC7-4FE66705242DQ33842381-CF36A2A6-D38A-46CE-97EC-FE424BF094ACQ33872581-1565DA9A-9330-4A9C-9D73-4EF95BE3ED59Q34002840-BE46161B-D5E4-445F-B0B3-699ED765644CQ34281402-052A7984-E171-479E-ADC2-7A3EC99854A8Q34631577-F7B14209-21D0-4BCF-84BA-A0A0626E5E56Q35194065-2366B7B5-A1E5-4425-94F3-E55E827A9D92Q36050418-A85B5FA7-5C85-480A-A4E6-A8CE14A03AABQ36170377-B2D6E6BE-8E77-4D3E-88AD-44FF015A07BCQ36452792-3645B313-D186-4D92-9936-1A88CA46C2F9Q37329555-A6EBECD6-5F4C-42DF-BD51-7E9957F01162Q37627644-BB1ABD1C-A0EF-479E-8368-D73CA0E08251Q37735710-C215E81D-2B68-41CD-A1E9-4AB5E55056B8Q37928941-4E9CE1BF-8C10-4EAE-9486-20778ECEF7FAQ37969225-05C7EDB4-CB96-4124-8638-B237DBDE2D15Q38131864-D0B4CCD1-AFAA-4967-8949-807F75FE2879Q38148200-B6183674-E611-4D9B-932D-99917F0DCFC4Q38624033-670C267E-24A1-4CDB-AB69-A93A7CA548B3Q39279314-F4F6CA60-F2E4-4730-A21F-B09CC1F84A4FQ39672604-DF4E0370-3CCE-45B4-96D3-925EC61C6151Q40917406-92613587-BCB1-415B-BE50-5F425D1A36BFQ41914835-2947C2AB-6624-4E7E-BF41-504A86F7315FQ42976189-51B08D80-4FCD-4F58-B856-49E537D66B89Q44144195-74DA3EF5-9CA9-41FA-96DD-4199C63F39C2Q50277574-2B12CEE9-2D6E-4A86-98A9-01505E46D0D6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral iron chelators.
@en
type
label
Oral iron chelators.
@en
prefLabel
Oral iron chelators.
@en
P1476
Oral iron chelators.
@en
P2093
Maria Domenica Cappellini
Paolo Pattoneri
P356
10.1146/ANNUREV.MED.60.041807.123243
P577
2009-01-01T00:00:00Z